Fennec Pharmaceuticals Inc.

NasdaqCM:FENC Stock Report

Market Cap: US$304.6m

Fennec Pharmaceuticals Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqCM:FENC Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
01 Jun 26BuyUS$38,213Rostislav RaykovIndividual18,375US$2.45
01 Jun 26SellUS$93,766Rostislav RaykovIndividual9,747US$9.62
01 Apr 26BuyUS$38,215Rostislav RaykovIndividual15,598US$2.45
01 Apr 26SellUS$69,069Rostislav RaykovIndividual10,946US$6.31
30 Mar 26BuyUS$19,881Christiana CioffiIndividual4,700US$4.23
02 Mar 26BuyUS$38,215Rostislav RaykovIndividual20,806US$2.45
02 Mar 26SellUS$84,361Rostislav RaykovIndividual10,079US$8.37
19 Feb 26BuyUS$9,996Robert AndradeIndividual29,735US$4.08
14 Jan 26BuyUS$24,500Robert AndradeIndividual10,000US$2.45
07 Jan 26BuyUS$34,751Robert AndradeIndividual14,184US$2.45
24 Dec 25SellUS$7,500,000Southpoint Capital Advisors LPCompany1,000,000US$7.50
18 Nov 25SellUS$170,048Southpoint Capital Advisors LPCompany19,341US$8.79
17 Nov 25SellUS$2,035,625Southpoint Capital Advisors LPCompany246,018US$8.79
17 Nov 25SellUS$2,035,625Southpoint Capital Advisors LPCompany246,018US$8.79
10 Oct 25BuyUS$4,996Chris RallisIndividual4,062US$1.23
10 Oct 25SellUS$16,401Chris RallisIndividual1,775US$9.24
09 Oct 25SellUS$636,229Southpoint Capital Advisors LPCompany67,114US$9.59
09 Oct 25SellUS$636,170Southpoint Capital Advisors LPCompany67,114US$9.59
08 Oct 25BuyUS$11,292Rostislav RaykovIndividual4,609US$2.45
11 Sep 25BuyUS$88,707Rostislav RaykovIndividual36,207US$2.45

Insider Trading Volume

Insider Buying: FENC insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of FENC?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders3,799,08410.9%
Private Companies3,993,69411.5%
Institutions6,108,21017.6%
General Public8,112,04423.4%
Hedge Funds12,723,99836.6%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 25.8%.

Top Shareholders

Top 25 shareholders own 72.64% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
11.5%
Alfasigma S.p.A.
3,993,694US$35.0m0%no data
8.37%
Rosalind Advisors, Inc.
2,908,201US$25.5m11.3%11.0%
7.91%
Rostislav Raykov
2,746,104US$24.1m2,410%no data
7.9%
Southpoint Capital Advisors LP
2,744,741US$24.1m0%0.45%
7.51%
Sonic GP LLC
2,607,357US$22.9m0%100.0%
7.15%
Solas Capital Management, LLC
2,482,198US$21.8m-3.07%11.56%
5.7%
Aigh Capital Management, LLC
1,981,501US$17.4m25.3%2.19%
3.94%
BlackRock, Inc.
1,368,176US$12.0m10.9%no data
2.58%
Vanguard Capital Management, LLC
897,144US$7.9m0%no data
2.07%
AWM Investment Company Inc
720,135US$6.3m1.16%0.52%
1.07%
Geode Capital Management, LLC
371,738US$3.3m25.1%no data
1.03%
State Street Global Advisors, Inc.
359,055US$3.1m1.78%no data
0.92%
Robert Andrade
321,113US$2.8m12.3%no data
0.65%
Potomac Capital Management Inc.
224,400US$2.0m136%1.5%
0.62%
Khalid Islam
213,825US$1.9m0%no data
0.55%
Kam Lawrence
192,602US$1.7m0%no data
0.51%
Eaton Vance Management
177,027US$1.6m-1.69%no data
0.48%
Vanguard Portfolio Management, LLC
168,473US$1.5m0%no data
0.44%
Citadel Advisors LLC
153,610US$1.3m-23.1%no data
0.44%
Northern Trust Global Investments
152,123US$1.3m35.7%no data
0.32%
Lion Point Capital, LP
112,434US$986.0k0%3.59%
0.3%
Cornerstone Capital, Inc.
105,000US$920.8k0%0.09%
0.24%
Tontine Management, LLC
83,024US$728.1k-40.5%0.01%
0.24%
Bridgeway Capital Management, LLC
83,005US$727.9k0%0.01%
0.19%
Steven Salamon
66,666US$584.7k0%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/10 01:22
End of Day Share Price 2026/06/10 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Fennec Pharmaceuticals Inc. is covered by 10 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Mayank MamtaniB. Riley Securities, Inc.
Madison Wynne El-SaadiB. Riley Securities, Inc.
Naureen QuibriaCapital One Securities, Inc.